Evidence map›Paper›PMID 34756932›Full record

ArticleProgress in neuro-psychopharmacology & biological psychiatry2022

Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.

Lusi Zhang, Scot Kristian Hill, Bin Guo, Baolin Wu, Ney Alliey-Rodriguez, Seenae Eum, Paulo Lizano, Elena I Ivleva, James L Reilly, Richard S E Keefe and 8 more

Open access · greenAbstract read
In one paragraph

Article in Progress in neuro-psychopharmacology & biological psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 1 country.

Lusi ZhangDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States of America.
Scot Kristian HillDepartment of Psychology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States of America.
Bin GuoDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, United States of America.
Baolin WuDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, United States of America.
Ney Alliey-RodriguezDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, United States of America.
Seenae EumDepartment of Pharmacogenomics, School of Pharmacy, Shenandoah University, Fairfax, VA, United States of America.
Paulo LizanoDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
Elena I IvlevaDepartment of Psychiatry, Southwestern Medical Center, University of Texas, Dallas, TX, United States of America.
James L ReillyDepartment of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.
Richard S E KeefeDepartments of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States of America.
Sarah K KeedyDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, United States of America.
Carol A TammingaDepartment of Psychiatry, Southwestern Medical Center, University of Texas, Dallas, TX, United States of America.
Godfrey D PearlsonDepartments of Psychiatry and Neurobiology, School of Medicine, Yale University, New Haven, CT, United States of America.
Brett A ClementzDepartment of Psychology and Neuroscience, University of Georgia, Athens, GA, United States of America.
Matcheri S KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
Elliot S GershonDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, United States of America.
John A SweeneyDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, United States of America.
Jeffrey R BishopDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States of America; Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN, United States of America. Electronic address: jrbishop@umn.edu.
University of Chicago · USUniversity of Minnesota · USThe University of Texas Southwestern Medical Center · USBeth Israel Deaconess Medical Center · USDuke Medical Center · USHarvard University · USNorthwestern University · USRosalind Franklin University of Medicine and Science · USShenandoah University · USUniversity of Cincinnati · USUniversity of Georgia · USUniversity of Minnesota Medical Center · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077851 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TAMMINGA, CAROL A · 2007 to 2019
$7.8M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077945 · NIMH · YALE UNIVERSITY · PI PEARLSON, GODFREY D · 2007 to 2019
$7.6M
Stability of Biotypes: a Longitudinal EvaluationR01MH078113 · NIMH · WAYNE STATE UNIVERSITY · PI KESHAVAN, MATCHERI S. · 2007 to 2019
$6.2M
Stability of Biotypes: a Longitudinal Evaluation (STABLE)R01MH103368 · NIMH · UNIVERSITY OF CHICAGO · PI GERSHON, ELLIOT S, KEEDY, SARAH K · 2015 to 2019
$4.5M
5/5 BIPOLAR-SCHIZOPHRENIA NETWORK FOR INTERMEDIATE PHENOTYPES (B-SNIP) - Resubmission - 1R01MH103366 · NIMH · UNIVERSITY OF GEORGIA · PI CLEMENTZ, BRETT A, GIBBONS, ROBERT D · 2015 to 2019
$3.8M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077852 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI THAKER, GUNVANT K · 2007 to 2010
$3.5M
Bipolar & Schizophrenia Consortium for Parsing Intermediate PhenotypesR01MH077862 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI SWEENEY, JOHN A · 2007 to 2010
$3.1M
1/5 - Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)R01MH124813 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TAMMINGA, CAROL A · 2021 to 2025
$1.8M
Schizophrenia Pharmacogenetics: cognition and symptom response to antipsychoticsK08MH083888 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BISHOP, JEFFREY R · 2009 to 2013
$899k
Antipsychotic Treatment Effects on Attention & Working Memory in SchizophreniaK23MH083126 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REILLY, JAMES L · 2009 to 2013
$819k
Enhancing Cognition in SchizophreniaK23MH072767 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HILL, SCOT KRISTIAN · 2006 to 2010
$794k
NCATS NIH HHS UL1 TR001863NIMH NIH HHS K08 MH083888NIMH NIH HHS K23 MH072767NIMH NIH HHS K23 MH083126NIMH NIH HHS R01 MH077851NIMH NIH HHS R01 MH077852NIMH NIH HHS R01 MH077862NIMH NIH HHS R01 MH077945NIMH NIH HHS R01 MH078113NIMH NIH HHS R01 MH103366NIMH NIH HHS R01 MH103368NIMH NIH HHS R01 MH124813
6 · The paper itself

Abstract

backgroundCognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not been established.

methodsNeuropsychological performance using the Brief Assessment of Cognition in Schizophrenia (BACS) was assessed in 616 individuals of European ancestry (403 psychosis, 213 controls). Polygenic risk scores for coronary artery disease (PRS

resultsHigher PRS

conclusionsHigher PRS

Indexed as

Cognitive DysfunctionAdultCardiovascular AgentsCoronary Artery DiseaseFemaleHumansMaleNeuropsychological TestsPsychotic DisordersWhite PeopleCardiovascular AgentsCardiovascular medicationCognitionCoronary artery diseasePolygenic risk scorePsychosis

Identifiers

PMID34756932
PMCPMC8932335
OpenAlexW3211145128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.